Pharmaceuticals is one of the deepest leadership markets in India. Generic manufacturing built the industry; specialty, biosimilars and complex generics are defining its next chapter.
Indian pharma is in transition. The generic export model that built the industry is maturing and competitive; the next decade will be shaped by specialty, biosimilars, complex generics, and the increasingly visible branded-domestic story.
Leadership demand reflects this. R&D leaders with deep specialty experience, regulatory heads who have lived through global filings, commercial leaders comfortable with both domestic and US markets, and CEOs who can balance scale with the next move into more sophisticated portfolios.
We are retained on senior mandates across listed Indian pharma, large private players, and multinationals operating in or from India.
The people who can run a US-facing generics P&L and those who can build a domestic branded franchise are rarely the same — and boards increasingly want both instincts in the leadership team.
Regulatory and quality leadership has moved from the back office to the boardroom. A single regulator observation can reset a company's trajectory, and the leaders who keep that from happening are scarce.
The shift from plain generics toward specialty, biosimilars and complex generics is rewriting the senior skill set faster than the talent pool refreshes.